NEW YORK (GenomeWeb) — Paragon Genomics said today that it has signed a global distribution agreement with MGI Tech for certain of the companies' respective next-generation sequencing panels and sample prep products.
Under the terms of the non-exclusive agreement, MGI Tech — a subsidiary of China's BGI — will distribute Paragon's CleanPlex next-generation sequencing panels for use with its own sequencing platforms worldwide except for the US. Additionally, Paragon will distribute MGI's MGISP-100RS, MGISP-960RS, and future automated sample prep systems in the US and Canada.
Additional terms were not disclosed.
Paragon added that its CleanPlex target enrichment chemistry — which uses proprietary amplicon sequencing technology to remove nonspecific PCR products generated during highly multiplexed PCR reactions — will be validated on MGI's systems. It is also joining MGI's compatible partner program, and the companies will collaborate on marketing and promotional activities in support of their alliance.
Last year, Hayward, California-based Paragon signed an agreement to integrate its CleanPlex technologies into Sophia Genetics' AI platform. Paragon also recently introduced a research-use-only CleanPlex panel for lung cancer in addition to its existing cancer, mitochondrial disease, and custom design panels.